Verrica Pharmaceuticals (VRCA)
(Delayed Data from NSDQ)
$6.79 USD
-0.06 (-0.88%)
Updated Apr 24, 2024 04:00 PM ET
After-Market: $6.82 +0.03 (0.44%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth B Momentum F VGM
Fundamental Charts
About Cash from Investing (Quarterly)
The company's quarterly Cash from Investing value is the sum of the company's current quarter cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
VRCA 6.79 -0.06(-0.88%)
Will VRCA be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for VRCA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VRCA
Ligand (LGND) Up 9% on FDA Nod for Molluscum Infection Gel
Best Momentum Stocks to Buy for April 18th
VRCA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Catalyst Pharmaceuticals (CPRX) Q2 Earnings Top, Revenues Up
Corcept (CORT) Down on Q2 Earnings Miss, Revenues Rise Y/Y
Zoetis' (ZTS) Q2 Earnings Miss Estimates, Revenues Up
Other News for VRCA
Understanding the Miscommunication: Clarifying Requests for Report Summaries
Verrica Pharmaceuticals Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference
Verrica Pharma gains as FDA lists Ycanth in Orange Book
Verrica Pharmaceuticals Announces that YCANTHâ„¢ Receives New Chemical Entity Status and Orange Book Listing from the FDA
Verrica announces YCANTH receives new chemical entity status